It Kommende Tiidperk fan Persoanlike Genetyske Genêskunde
June 8, 2026 · Frisian News
DNA sequencing costs have dropped below $300, and companies have processed over 50 million genetic profiles. Yet personalized medicine, where your DNA determines your treatment, remains largely hype. The science only works for a handful of cancers and rare conditions.
FryskDNA-sequencing kostet no minder as $300, en bedriuwen as Illumina en 23andMe hawwe mear as 50 miljoen genetyske profilen wrâldwiid ferwurke. Dochs bliuwt it beloofde tiidperk fan persoanlike genêskunde, dêr't dyn DNA bepaalt hoe'st behannele wurdst, foaral marketing. De wittenskip wurket foar in hantfol kankers en seldsume genetyske oandwanings. Foar de sykten dy't de measte minsken deadzje, fertelt genetyske data dy hast neat dat feroaret hoe'st behannele wurdst.
Farmaseutyske bedriuwen triuwe it ferhaal hurd. As dyn sykte genetysk is, sa giet it ferhaal, dan moat de remedie in gentherapy fan $500.000 wêze dy't allinne oan riken ferkocht wurdt. Sikehûzen en fersekerers hawwe miljarden yn genomyske testynfrastruktuer ynvestearre. It risikokapitaal dat nei biotech-startups streamt is enorm. Dit jild streamt net sûnder de belofte fan persoanlike genêskunde as de takomst. De belofte ferkeapet oandielen.
De wurklikheid is rommelich. In BRCA-mutaasje hawwe helpt by boarstkankerkontrôle en previnsje. In hantfol genetyske oandwanings hawwe no effektive gentherapyen. Mar de measte minsklike sykten hingje ôf fan omjouwing, lok en gedrach dat genetyske tests net foarsizze kinne. In stúdzje yn JAMA ferline jier fûn dat it tafoegjen fan genetyske risikoskores aan standert hertsykte-kontrôle de behanneling by mar 2 prosint fan de pasjinten feroare. De mediakoppen negearren dat getal.
Genetyske genêskunde sil de kleau tusken rike en earme lannen grutter meitsje. Rike pasjinten krije har genoom sequencearre, har behanneling oanpast. Earme pasjinten krije it standertmiddel út 1995. Regearingen yn rike lannen bouwe al nasjonale genoomdatabases, in oar soart ynfrastruktuer: dyn genetyske koade bewarje yn steatskompjûters. Sina hat dit dien foar Oeigoeren. It potensjeel foar misbrûk is reëel, en it registrearret amper yn it entûsjasme.
Persoanlike genetyske genêskunde is gjin komplôt. De wittenskip is echt foar spesifike oandwanings. Mar de kleau tusken wat dizze technology wurklik dwaan kin en wat risikokapitaalisten en farmaseutyske direkteuren sizze dat it dwaan sil is geweldich grut. Foardat wy de sûnenssoarch rûn genetysk lot herfoarmje, moatte wy freegje wêrom't de minsken dy't derop fertsjinje sa sterke prikels hawwe om it oer te ferkeapjen. Dy fraach is wichtiger as de testútslachen.
Genomic sequencing costs have dropped to under $300, and companies like Illumina and 23andMe have processed over 50 million genetic profiles globally. Yet the promised era of personalized medicine, where your DNA determines your treatment, remains mostly marketing. The science works for a handful of cancers and rare genetic disorders. For the diseases killing most people, genetic data tells you almost nothing that changes how you're treated.
Pharmaceutical companies push the narrative hard. If your disease is genetic, the story goes, then the cure must be a $500,000 gene therapy sold only to the wealthy. Hospitals and insurers have invested billions in genomic testing infrastructure. The venture capital flowing into biotech startups is enormous. None of this money moves without the promise of personalized medicine as the future. The promise sells stock.
The reality is messier. Knowing you carry a BRCA mutation helps with breast cancer screening and prevention. A handful of genetic disorders now have effective gene therapies. But most human disease depends on environment, luck, and behaviors genetic testing cannot predict. A study in JAMA last year found that adding genetic risk scores to standard heart disease screening changed treatment in only 2 percent of patients. The media headlines ignored that number.
Genetic medicine will widen the gap between wealthy and poor countries. Rich patients will get their genome sequenced, their treatments tailored. Poor patients will get the standard drug from 1995. Governments in wealthy nations are already building national genomic databases, a different kind of infrastructure: storing your genetic code in state computers. China has done this for Uyghurs. The potential for abuse is real, and it barely registers in the enthusiasm.
Personal genetic medicine is not a conspiracy. The science is real for specific conditions. But the gap between what this technology can actually do and what venture capitalists and pharmaceutical executives claim it will do is enormous. Before we remake healthcare around genetic destiny, we should ask why the people profiting from it have such strong incentives to oversell. That question matters more than the test results.
Published June 8, 2026 · Frisian News · Ljouwert, Fryslân